BACKGROUND Patients with chronic obstructive pulmonary disease (COPD) have increased risk of cardiovascular
ischemic heart disease and stroke, accounts for 1 in 4 deaths globally and is increasing in prevalence (1) . Despite recent advances in understanding risk factors and therapeutic interventions, atherosclerotic events remain unacceptably common.
Residual risk is particularly high among patients with proinflammatory comorbidities, such as chronic obstructive pulmonary disease (COPD) (2) . In some cases, it remains unclear whether it is the disease process itself, or the off-target effects of the pharmaco- 
SUMMIT (Study to Understand Mortality and
MorbidITy) (13, 14) assessed the efficacy and safety of inhaled corticosteroids and longacting beta-agonists (LABAs) in 16,485 patients with COPD and heightened CV risk. This was a multimorbid population with interventions that could have both benefit (15) and harm (16) . The present study reports post hoc analyses aiming to determine whether plasma high-sensitivity cardiac troponin I concentrations can stratify CV risk, be modified by inhaled corticosteroids (ICS) and bronchodilators, and predict outcomes within the context of SUMMIT. Adamson et al. where the best fitting model was selected from a variety of polynomial or logarithmic models using 2-term fractional polynomials (20) .
S E P T E M B E R
Previous reports have identified that adverse CV outcomes are associated with plasma troponin I concentrations $5 ng/l (12, 21) . To explore this association further, and investigate whether the predictive value of this threshold could be applied to the SUMMIT population, patients were grouped into those who had plasma concentrations <5 ng/l at both baseline and 3 months, and those with a concentration $5 ng/l at either baseline or 3 months.
Scientific oversight of the trial was provided by a steering committee composed of academic experts and employees from GlaxoSmithKline, who were collectively responsible for the study design and analysis, and for the review and interpretation of the data. This study is registered with ClinicalTrials.gov (NCT01313676).
RESULTS
The study population and principal findings of the SUMMIT study have previously been described (14) . Congestive heart failure 15 (5) 11 (3) 21 (7) 34 (10) 61 (19) 146 (9) (27) 87 (27) 81 (25) 78 (24) 92 (29) 439 (26) 4,111 (25) Fluticasone furoate 69 (22) 87 (27) 83 (26) 76 (23) 74 (23) 415 (25) 4,135 (25) Vilanterol 87 (28) 84 (26) 70 (22) 80 (24) 77 (24) 416 (25) 4,118 (25) Combination therapy 68 (22) 67 (21) 85 (27) 96 (29) 75 (24) 403 (24) 4,121 (25) Values are mean AE SD or n (%). *Of the 1,673 patients in the biomarker population, 74 did not have baseline cardiac troponin I measured and are therefore not included in the cardiac troponin I quintiles and analyses.
BMI ¼ body mass index; CVD ¼ cardiovascular disease; FEV1 ¼ forced expiratory volume in 1 s; GFR ¼ glomerular filtration rate; ITT-E ¼ intention-to-treat efficacy.
quintile (<2.3 ng/l), patients in the highest quintile ($7.7 ng/l) were older, more likely to be male, former smokers, have higher systolic blood pressure, a history of ischemic heart disease, coronary artery disease, congestive heart failure, hypercholesterolemia, hypertension, diabetes mellitus, a family history of myocardial infarction or stroke, and to be receiving treatment with antiplatelet and statin therapies.
A number of patient characteristics were associated with baseline plasma cardiac troponin I concentration ( Table 2 Compared with the lowest quintile, participants in the highest quintile were at greater risk of experiencing a CV composite event ( Figure 1A) . This difference persisted after adjustment for confounding variables including CV risk factors ( Abbreviations as in Table 1 .
Adamson et al. Patients experiencing CV event* 5 (2) 9 (3) 16 (5) 23 (7) 21 (7) Quintile vs. 1st quintile Values are n (%) unless otherwise noted. *Composite CV event comprising any of: CV death, myocardial infarction, stroke, unstable angina, and transient ischemic attack. †Cox proportional hazards model adjusted for inhaled treatment, age, sex, previous myocardial infarction, hypertension. ‡Cox proportional hazards model adjusted for inhaled treatment, age, sex, previous myocardial infarction, hypertension, previous COPD exacerbation history.
CI ¼ confidence interval; COPD ¼ chronic obstructive pulmonary disease; CV ¼ cardiovascular.
Adamson et al. This study has a number of notable strengths that distinguish it from previous reports on the use of plasma cardiac troponin within the outpatient setting. The association between baseline high-sensitivity cardiac troponin I and CV death (orange) and COPD exacerbations (blue) was examined using cardiac troponin as a continuous variable. Hazard ratios are compared with the median troponin concentration in the first quintile (1.7 ng/l) and are adjusted for age, sex, previous myocardial infarction, hypertension, and exacerbation history. Shaded areas represent 95% confidence intervals. COPD ¼ chronic obstructive pulmonary disease; CV ¼ cardiovascular.
JACC VOL. 72, NO. 10, 2018 Adamson et al. troponin quintiles is similar to that seen in both primary and secondary CV disease prevention populations, reinforcing its broad applicability for prognostic stratification (7, 11, 12 and CV death (B). By contrast, there was no difference in COPD exacerbations (C). Abbreviations as in Figure 1 . 
CONCLUSIONS
In patients with combined respiratory and CV diseases, high-sensitivity plasma cardiac troponin I concentration is a prognostic marker that is specific to 
